Mayur Ian Somaiya - 20 Jan 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Financial Officer
Signature
/s/ Louise Kooij by Power of Attorney from Mayur Ian Somaiya
Issuer symbol
NAMS
Transactions as of
20 Jan 2026
Net transactions value
-$2,334,618
Form type
4
Filing time
22 Jan 2026, 17:24:59 UTC
Previous filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Somaiya Mayur Ian Chief Financial Officer C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS /s/ Louise Kooij by Power of Attorney from Mayur Ian Somaiya 22 Jan 2026 0001760303

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Options Exercise $557,600 +60,216 +103% $9.26 118,598 20 Jan 2026 Direct
transaction NAMS Ordinary Shares Sale $27,576 -900 -0.76% $30.64 117,698 20 Jan 2026 Direct F1, F2
transaction NAMS Ordinary Shares Sale $1,262,047 -39,712 -34% $31.78 77,986 20 Jan 2026 Direct F1, F3
transaction NAMS Ordinary Shares Sale $634,778 -19,604 -25% $32.38 58,382 20 Jan 2026 Direct F1, F4
transaction NAMS Ordinary Shares Options Exercise $368,400 +39,784 +68% $9.26 98,166 21 Jan 2026 Direct
transaction NAMS Ordinary Shares Sale $512,782 -15,422 -16% $33.25 82,744 21 Jan 2026 Direct F1, F5
transaction NAMS Ordinary Shares Sale $823,436 -24,362 -29% $33.80 58,382 21 Jan 2026 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (Right to Buy) Options Exercise $0 -60,216 -7.9% $0.000000 702,598 20 Jan 2026 Ordinary Shares 60,216 $9.26 Direct F7
transaction NAMS Option (Right to Buy) Options Exercise $0 -39,784 -5.7% $0.000000 662,814 21 Jan 2026 Ordinary Shares 39,784 $9.26 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 These shares were sold in multiple transactions at prices ranging from $30.17 per share to $30.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F3 These shares were sold in multiple transactions at prices ranging from $31.29 per share to $32.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F4 These shares were sold in multiple transactions at prices ranging from $32.29 per share to $32.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F5 These shares were sold in multiple transactions at prices ranging from $32.48 per share to $33.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F6 These shares were sold in multiple transactions at prices ranging from $33.48 per share to $34.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F7 The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.